The global pharmaceutical industry experienced a 141% rise in company filings mentions of corporate governance in Q1 2023 compared with the previous quarter, with the highest share accounted for by GSK with 306% year-on-year increase, according to GlobalData’s analysis of over 898 pharmaceutical company filings. With an increasing focus on ESG, Pharmaceutical companies are under pressure to incorporate corporate governance. GlobalData’s ESG (Environmental, Social and Governance) Survey on Pharmaceutical Manufacturing – Towards a Sustainable Supply Chain report includes the ESG measures and response, and ESG Ratings of Pharmaceutical Companies as assessed by leading ESG rating agencies. Buy the report here.
Notably, corporate governance was one of the most frequently referenced themes in Q1 2023, ranking highest in terms of mentions, ahead of artificial intelligence and environment, according to GlobalData.
Of the 50 leading companies in the pharmaceutical industry, GSK had the greatest increase in references for corporate governance in Q1 2023, compared with the previous quarter. GlobalData identified 524 corporate governance-related sentences in the company's filings, an increase of 17300% in Q1 2023 compared with Q4 2022. Novartis’s mentions of corporate governance rose by 2500% to 267 and Pfizer’s by 1600% to 172 and Sanofi’s by 4800% to 149 and Novo Nordisk’s by 10200% to 103.
GlobalData’s Company Filings Analytics also applies sentiment weight to reference sentences, based on whether the sentences are positive, negative, or neutral. Starting at 100 in 2020, an index over 100 is more positive. The overall index for corporate governance in Q1 2023 was 87.
To further understand GlobalData's analysis on ESG (Environmental, Social and Governance) Survey on Pharmaceutical Manufacturing – Towards a Sustainable Supply Chain, buy the report here.